A pilot study of the effect of Gemfibrozil on some haematological parameters.
In a double-blind 13 week study the effects of Gemfibrozil were compared with placebo. Gemfibrozil was given to 10 patients with evidence of severe atherosclerosis; four similar patients acted as controls. As expected, in the treated group, total cholesterol and triglycerides decreased significantly and HDL cholesterol increased. The Fibrinogen did not change although the ESR increased markedly and the heparin neutralizing activity (HNA) of the plasma decreased (p = 0.01). The antithrombic activity increased. The change in the HNA correlated weakly to the total cholesterol both before and during treatment. These findings show that some of the effects of Gemfibrozil on atherosclerotic humans are similar to those of Clofibrate but others are different.
D000368:Aged; D001161:Arteriosclerosis / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D001780:Blood Coagulation Tests; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D005260:Female; D015248:Gemfibrozil; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D010421:Pentanoic Acids; D014280:Triglycerides; D014631:Valerates; D002784:Cholesterol; D015248:Gemfibrozil